Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Laquinimod - Active Biotech

Next Previous
X
Search
Drug Profile

Laquinimod - Active Biotech

Alternative Names: ABR-215062; Laquinimod sodium; Nerventra; SAIK-MS; TV-5600

Latest Information Update: 28 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Active Biotech
  • Developer Active Biotech; Icahn School of Medicine at Mount Sinai; National University of Singapore; Ruhr-University Bochum; Tel Aviv University; University College London; University of British Columbia
  • Class Amides; Anti-inflammatories; Chlorinated hydrocarbons; Eye disorder therapies; Neuropsychotherapeutics; Quinolones; Small molecules; Urologics
  • Mechanism of Action Aryl hydrocarbon receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease
  • New Molecular Entity Yes
  • Available For Licensing Yes - Crohn's disease; Uveitis

Highest Development Phases

  • Marketed Multiple sclerosis
  • Phase I Uveitis
  • Suspended Crohn's disease
  • No development reported Wet age-related macular degeneration
  • Discontinued Huntington's disease; Lupus nephritis; Systemic lupus erythematosus

Most Recent Events

  • 28 Jul 2024 No recent reports of development identified for preclinical development in Wet age-related macular degeneration in Sweden (Topical)
  • 22 Dec 2023 Global Ophthalmic Research Center plans a phase I LION study of laquinimod for the treatment of Uveitis in Q1 2024 (Ophthalmic, Drops) (NCT06161415)
  • 05 Dec 2023 Active Biotech and the Global Ophthalmic Research Center (GORC) entered into a clinical trial collaboration agreement for the treatment of Uveitis

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top